Which has the lower trailing P/E, MEDP or RVTY?

MEDP has the lower trailing P/E: MEDP trades at 36.11 and RVTY at 65.85. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, MEDP or RVTY?

Over the past five years, MEDP grew revenue faster — MEDP at a 22.03% CAGR versus RVTY at -9.69%.

Does MEDP or RVTY pay a bigger dividend?

RVTY pays a dividend (0.23% yield), while MEDP has no payments in the available dividend history.

Is MEDP or RVTY more profitable?

MEDP runs the higher net margin — MEDP at 17.67% versus RVTY at 8.16%.

How have MEDP and RVTY total returns compared?

Over the past 10 years, MEDP delivered 34.83% and RVTY delivered 9.26% annualized total return. Past performance doesn't predict future results.

Medpace Holdings, Inc. (MEDP) vs Revvity, Inc. (RVTY)

A side-by-side comparison of Medpace Holdings, Inc. and Revvity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

MEDP

Medpace Holdings, Inc.

$17.20B

$616.33HealthcareDelayed quote: Sep 15, 2026, 1:05 PM EDT

RVTY

Revvity, Inc.

$15.43B

$138.28HealthcareDelayed quote: Sep 15, 2026, 1:05 PM EDT

Total return — MEDP vs RVTY

growth of $100 · dividends reinvested · last 10y

MEDP +1874.9% (+34.8%/yr)RVTY +137.9% (+9.1%/yr)MEDP compounded faster over this window

Log scale — wide-divergence pair

MEDP RVTY

MEDP vs RVTY: by the numbers

•MEDP is the larger company ($17.20B vs $15.43B market cap).
•MEDP trades at the lower trailing earnings multiple (36.11 vs 65.85 P/E), one valuation lens rather than an overall verdict.
•MEDP converts more revenue to profit (17.67% vs 8.16% net margin).
•MEDP grew revenue faster over the past five years (22.03% vs -9.69% CAGR).
•RVTY pays a dividend (0.23% yield), while MEDP has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	MEDP	RVTY
P/E ratio	36.11	65.85
Forward P/E	35.01	25.82
P/S ratio	6.18	5.30
P/B ratio	39.65	2.13
EV / EBITDA	27.52	23.01
FCF yield	4.08%	3.63%

Profitability

Metric	MEDP	RVTY
Gross margin	28.76%	52.11%
Operating margin	20.97%	12.32%
Net margin	17.67%	8.16%
ROE	113.29%	3.29%
ROIC	77.00%	2.91%

Dividends

Metric	MEDP	RVTY
Dividend yield	N/A	0.23%
Payout ratio	N/A	13.33%

Growth (annualized)

Metric	MEDP	RVTY
Revenue CAGR (5Y)	22.03%	-9.69%
EPS CAGR (5Y)	30.90%	-20.48%
FCF CAGR (5Y)	23.40%	-16.48%
Total return CAGR (5Y)	25.09%	-7.62%

Frequently asked

Which has the lower trailing P/E, MEDP or RVTY?: MEDP has the lower trailing P/E: MEDP trades at 36.11 and RVTY at 65.85. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, MEDP or RVTY?: Over the past five years, MEDP grew revenue faster — MEDP at a 22.03% CAGR versus RVTY at -9.69%.
Does MEDP or RVTY pay a bigger dividend?: RVTY pays a dividend (0.23% yield), while MEDP has no payments in the available dividend history.
Is MEDP or RVTY more profitable?: MEDP runs the higher net margin — MEDP at 17.67% versus RVTY at 8.16%.
How have MEDP and RVTY total returns compared?: Over the past 10 years, MEDP delivered 34.83% and RVTY delivered 9.26% annualized total return. Past performance doesn't predict future results.

Go deeper

Full MEDP analysis Full RVTY analysis Interactive comparison tool

Dig into the metrics

Medpace P/E ratio Revvity P/E ratio Revvity dividend yield Medpace ROE Revvity ROE Medpace operating margin Revvity operating margin Medpace revenue growth Revvity revenue growth Medpace free cash flow Revvity free cash flow

Medpace & Revvity appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.